Maldonado-Avila Miguel, Garduno-Arteaga Leopoldo, Jungfermann-Guzman Rene, Manzanilla-Garcia Hugo A, Rosas-Nava Emmanuel, Procuna-Hernandez Nestor, Vela-Mollinedo Alejandro, Almazan-Trevino Luis, Guzman-Esquivel Jose
Departamento de Urologia, Hospital Geral de Mexico, Ciudad de Mexico.
Instituto Mexicano del Seguro Social Colima, no México.
Int Braz J Urol. 2016 May-Jun;42(3):487-93. doi: 10.1590/S1677-5538.IBJU.2015.0186.
Indwelling double J ureteral stents are used routinely in the resolution of ureteral obstruction caused by different etiologies. Evaluation of urinary symptoms related to double-J stent, indicate that these affect 73-90% of patients. We conducted a prospective, randomized study, to evaluate the efficacy of tamsulosin, oxybutinin and combination therapy in improving the urinary symptoms.
Patients who underwent ureteral stent placement after ureterolithotripsy (total 51), were randomized into three groups: Group I: Tamsulosin 0.4 mg. Once per day(17 patients), Group II: Oxybutinin 5 mg. once per day (17 patients), Group III: Tamsulosin+ oxybutynin once per day (17 patients). All the groups received the drugs for three weeks and completed a Spanish validated Ureteral Stent Symptom Questionnaire (USSQ) at day 7 and 21.
Repeated measures ANOVA showed mean urinary symptom index score was 22.3 vs. 15.5 in group three (p<0.001) at day 7 and 21 respectively. The mean work performance index was 6.6 vs 8.1 (p=0.049) favoring tamsulosin group, the mean sexual score was 0.5 vs 1.5 (p=0.03). Among additional problems the mean was 7.2 vs 6.2 (p=0.03). No significant difference was noted among pain and general health index. No side effects were reported.
Combination therapy with tamsulosin and oxybutynin improved irritative symptoms and work performance as well as sexual matters. Combination therapy should be considered for patients who complained of stent related symptoms.
留置双J输尿管支架常用于解决由不同病因引起的输尿管梗阻。对与双J支架相关的泌尿系统症状的评估表明,这些症状影响73%至90%的患者。我们进行了一项前瞻性随机研究,以评估坦索罗辛、奥昔布宁及联合治疗改善泌尿系统症状的疗效。
输尿管镜碎石术后接受输尿管支架置入的患者(共51例)被随机分为三组:第一组:坦索罗辛0.4毫克,每日一次(17例患者);第二组:奥昔布宁5毫克,每日一次(17例患者);第三组:坦索罗辛+奥昔布宁,每日一次(17例患者)。所有组均接受药物治疗三周,并在第7天和第21天完成一份经西班牙验证的输尿管支架症状问卷(USSQ)。
重复测量方差分析显示,第7天和第21天,第三组的平均泌尿系统症状指数评分分别为22.3和15.5(p<0.001)。有利于坦索罗辛组的平均工作表现指数为6.6对8.1(p=0.049),平均性功能评分是0.5对1.5(p=0.03)。在其他问题方面,平均值为7.2对6.2(p=0.03)。疼痛和总体健康指数之间未观察到显著差异。未报告有副作用。
坦索罗辛与奥昔布宁联合治疗改善了刺激性症状、工作表现以及性功能问题。对于抱怨有支架相关症状的患者,应考虑联合治疗。